In vivo dynamic distribution of 131I-glucagon-like peptide-1 (7-36) amide in the rat studied by gamma camera

Nuclear Medicine and Biology

Volumn 26, Issue 4, 1999, Pages 413-420

  Hassan, Moustapha ^a,b   Eskilsson, Anja ^c   Nilsson, Christina ^a   Jonsson, Cathrine ^d   Jacobsson, Hans ^a   Refai, Essam ^b   Larsson, Stig ^d   Efendic, Suad ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Diabetes; Distribution; Gamma camera; GLP 1; Glucagon like peptide; Pharmacokinetics

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; IODINE 131;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; DOSE RESPONSE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; NONHUMAN; RADIOIODINATION; RADIOISOTOPE DISTRIBUTION; RAT; SCINTILLATION CAMERA;

ANIMALS; BRAIN; GAMMA CAMERAS; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; IODINE RADIOISOTOPES; MALE; METABOLIC CLEARANCE RATE; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 0032982308     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(98)00121-8     Document Type: Article

References (34)

1. Bullock B.P., Heller R.S., Habener J.F. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. 137:1996;2968-2978.
2. Calvo J.C., Gisolfi C.V., Blazquez E., Mora F. Glucagon-like peptide-1(7-36)amide induces the release of aspartic acid and glutamine by the ventromedial hypothalamus of the conscious rat. Brain Res. Bull. 38:1995;435-439.
3. Calvo J.C., Yusta B., Mora F., Blazquez E. Structural characterization by affinity cross-linking of glucagon-like peptide-1(7-36)amide receptor in rat brain. J. Neurochem. 64:1995;299-306.
4. Deacon C.F., Johnsen A.H., Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminanally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80:1995;952-957.
5. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 44:1995;1126-1131.
6. Drucker D.J. Glucagon and the glucagon-like peptides. Pancreas. 5:1990;484-488.
7. Drucker D.J., Asa S. Glucagon gene expression in vertebrate brain. J. Biol. Chem. 263:1988;13475-13478.
8. Dupré J., Behme M.T., Hramiak I.M., McDonald T.J. Subcutanous glucagon-like peptide 1 combined with insulin normalizes postcibal glycemic excursions in IDDM. Diabetes Care. 20:1997;381-384.
9. Egan J.M., Montrose-Rafizadeh C., Wang Y., Bernier M., Roth J. Glucagon-like peptide-1 (7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes One of several potential extrapancreatic sites of GLP-1 action . Endocrinology. 135:1994;2070-2075.
10. Göke R., Larsen P.J., Mikkelsen J.D., Sheikh S.P. Distribution of GLP-1 binding sites in rat brain evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur. J. Neurosci. 7:1995;2294-2300.
11. Gutniak M., Ørskov C., Holst J.J., Ahrén B., Efendic S. Antidiabetic effect of glucagon-like peptide-1(7-36)amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 326:1992;1316-1322.
12. Guyton A.C. Textbook of Medical Physiology. 8th edn. 1991;W. B. Sanders Company, Baltimore.
13. Holst J.J., Ørskov C., Vagn Nielsen O., Schwartz T.W. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett. 211:1987;169-174.
14. Juntti-Berggren L., Pigon J., Karpe F., Hamsten A., Gutniak M., Vignati L., Efendic S. The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients. Diabetes Care. 19:1996;1200-1206.
15. Kieffer T.J., McIntosh C.H.S., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 136:1995;3586-3596.
16. Kreymann B., Ghatei M.A., Williams G., Bloom S.R. Glucagon-like peptide-1 7-36 a physiological incretin in man. Lancet. 5:1987;1300-1304.
17. Mentlein R., Gallwitz B., Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214:1993;829-835.
18. Merida E., Delgado E., Molina L.M., Villanueva-Penacarrillo M.L., Valverde I. Presence of glucagon and glucagon-like peptide-1-(7-36)amide receptors in solubilized membranes of human adipose tissue. J. Clin. Endocrinol. Metab. 77:1993;1654-1657.
19. Nauck M.A., Kleine N., Ørskov C., Holst J.J., Willms B., Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 36:1993;741-744.
20. Nauck M.A., Wollschläger D., Werner J., Holst J.J., Ørskov C., Creutzfeldt W., Willms B. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia. 39:1996;1546-1553.
21. 2 A physiological inhibitor of gastric acid secretion in man . J. Endocrinol. 126:1990;169-173.
22. Ørskov C., Bersani M., Johnsen A.H., Højrup P., Holst J.J. Complete sequences of glucagon-like peptide-1 from human and pig small intestine. J. Biol. Chem. 264:1989;12826-12829.
23. Ørskov C., Jeppesen J., Madsbad S., Holst J.J. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J. Clin. Invest. 87:1991;415-423.
24. Ørskov C., Wettergren A., Holst J.J. Biological effects and metabolic rates of glucagon-like peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistingiushable. Diabetes. 42:1993;658-661.
25. Oshima I., Hirota M., Ohboshi C., Shima K. Comparison of half-disappearance times, distribution volumes and metabolic clearance rates of glucagon-like peptide 1 and glucagon in rats. Regul. Pept. 21:1988;85-93.
26. Rachman J., Barrow B.A., Levy J.C., Turner R.C. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia. 40:1997;205-211.
27. Ritzel R., Ørskov C., Holst J.J., Nauck M.A. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutanous injections in healthy volunteers. Dose-response-relationships. Diabetologia. 38:1995;720-725.
28. Ruiz-Grande C., Alarcón C., Alcántara A., Castilla C., López Novoa J.M., Villanueva-Penacarrillo M.L., Valverde I. Renal catabolism of truncated glucagon-like peptide-1. Horm. Metab. Res. 25:1993;612-616.
29. Ruiz-Grande C., Alarcón C., Mérida E., Valverde I. Lipolytic action of glucagon-like peptides in isolated rat adipocytes. Peptides. 13:1992;13-16.
30. Schirra J., Kuwert P., Wank U., Leicht P., Arnold R., Göke B., Katschinski M. Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men. Proceed. Assoc. Am. Phys. 109:1996;84-97.
31. Thorens B. Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc. Natl. Acad. Sci. USA. 89:1992;8641-8645.
32. Valverde I., Mérida E., Delgado E., Trapote M.A., Villanueva-Penacarrillo M.L. Presence and characterization of glucagon-like peptide-1(7-36)amide receptors in solubilized membranes of rat adipose tissue. Endocrinology. 132:1993;75-79.
33. Villanueva-Penacarrillo M.L., Delgado E., Trapote M.A., Alcántara A., Clemente F., Luque M.A., Perea A., Valverde I. Glucagon-like peptide-1 binding to rat hepatic membranes. J. Endocrinol. 146:1995;183-189.
34. Wettergren A., Petersen H., Ørskov C., Christiansen J., Sheikh S.P., Holst J.J. Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand. J. Gastroenterol. 29:1994;501-505.